BRAF mutant relapsed/refractory LCH was included in the tumor agnostic early phase trials discussed above in relation to LGG (dabrafenib - NCT01677741, trametinib +/- dabrafenib - NCT 02124772, vemurafenib (BRAF V600 inhibitor) or selumetinib (MEK inhibitor) arms, within the Pediatric MATCH Trial - NCT03220035). This evidence concerns the gene BRAF and neoplasm.